Update on emergence of HIV-1 resistance to antiretroviral drug classes in an Italian national database: 2007-2009

Clinical Microbiology and Infection

Volumn 17, Issue 9, 2011, Pages 1352-1355

  di Giambenedetto, S ^a   Prosperi, M ^a   Fanti, I ^a   Bruzzone, B ^b   Paolucci, S ^c   Penco, G ^d   Meini, G ^e   di Biagio, A ^b   Paolini, E ^f   Micheli, V ^g   Meraviglia, P ^g   Castelli, P ^h   Corsi, P ⁱ   Gonnelli, A ^j   Fabbiani, M ^a   Zazzi, M ^e   de Luca, A ^a,b  

^a CATHOLIC UNIVERSITY   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^d GALLIERA HOSPITAL   (Italy)

^e UNIVERSITY OF SIENA   (Italy)

^f CREMONA HOSPITAL   (Italy)

^g UNIVERSITY OF MILAN   (Italy)

^h H Macerata ^*  (Italy)

ⁱ CAREGGI UNIVERSITY HOSPITAL   (Italy)

^j UNIVERSITY HOSPITAL OF SIENA   (Italy)

more..

Author keywords

Antiretroviral therapy; Drug resistance mutations; Human immunodeficiency virus 1

Indexed keywords

ABACAVIR; DIDANOSINE; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RITONAVIR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ADULT; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; ITALY; MAJOR CLINICAL STUDY; MALE; PATIENT SELECTION; PRIORITY JOURNAL; VIRUS MUTATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 80051891486     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2011.03563.x     Document Type: Article

References (18)

1. Palella FJ, Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338: 853-860.
2. DeGruttola V, Dix L, D'Aquila R et al. The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antivir Ther 2000; 5: 41-48.
3. Hirsch MS, Brun-Vezinet F, Clotet B et al. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin Infect Dis 2003; 37: 113-128.
4. Gottlieb GS, Hawes SE, Agne HD et al. Lower levels of HIV RNA in semen in HIV-2 compared with HIV-1 infection: implications for differences in transmission. AIDS 2006; 20: 895-900.
5. Di Giambenedetto S, Bracciale L, Colafigli M et al. Declining prevalence of HIV-1 drug resistance in treatment-failing patients: a clinical cohort study. Antivir Ther 2007; 12: 835-839.
6. Di Giambenedetto S, Zazzi M, Corsi P et al. Evolution and predictors of HIV type-1 drug resistance in patients failing combination antiretroviral therapy in Italy. Antivir Ther 2009; 14: 359-369.
7. Hicks CB, Cahn P, Cooper DA et al. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials. Lancet 2006; 368: 466-475.
8. Clotet B, Bellos N, Molina JM et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet 2007; 369: 1169-1178.
9. Katlama C, Haubrich R, Lalezari J et al. Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48week analysis of two randomized, controlled trials. AIDS 2009; 23: 2289-2300.
10. Gulick RM, Lalezari J, Goodrich J et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 2008; 359: 1429-1441.
11. Steigbigel RT, Cooper DA, Teppler H et al. Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 phase iii trials. Clin Infect Dis 2010; 50: 605-612.
12. Raffi F, Katlama C, Saag M et al. Week-12 response to therapy as a predictor of week 24, 48, and 96 outcome in patients receiving the HIV fusion inhibitor enfuvirtide in the T-20 versus Optimized Regimen Only (TORO) trials. Clin Infect Dis 2006; 42: 870-877.
13. De Luca A, Di Giambenedetto S, Romano L et al. Frequency and treatment-related predictors of thymidine-analogue mutation patterns in HIV-1 isolates after unsuccessful antiretroviral therapy. J Infect Dis 2006; 193: 1219-1222.
14. Johnson VA, Brun-Vézinet F, Closet B et al. Update of the Drug Resistance Mutations in HIV-1. Top HIV Med 2009; 17: 138-145.
15. Di Giambenedetto S, Colafigli M, Pinnetti C et al. Genotypic resistance profile and clinical progression of treatment-experienced HIV type 1-infected patients with virological failure. AIDS Res Hum Retroviruses 2008; 24: 149-154.
16. Zaccarelli M, Tozzi V, Lorenzini P et al. Multiple drug class-wide resistance associated with poorer survival after treatment failure in a cohort of HIV-infected patients. AIDS 2005; 19: 1081-1089.
17. Cooper DA, Steigbigel RT, Gatell JM et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med 2008; 359: 355-365.
18. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents, January 1, 2011.